Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort

Segura, A. G ; Mané, A. ; Prohens, Ll. ; Rodríguez, N. ; Mezquida, G. ; Cuesta, M. J ; Vieta, E. ; Amoretti, S. ; Lobo, A. (Universidad de Zaragoza) ; González-Pinto, A. ; Díaz-Caneja, C. M. ; Roldán Bejarano, A. ; Jiménez, E. ; Baeza, I. ; Legido, T. ; Saiz-Ruiz, J. ; Bernardo, M. ; Mas, S. ; PEPs Group

Resumen: Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRSCUD reported increased baseline cannabis use. PRSCI was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.

Idioma: Inglés

DOI: 10.1016/j.psychres.2023.115249

Año: 2023

Publicado en: PSYCHIATRY RESEARCH 325 (2023), 115249 [7 pp.]
ISSN: 0165-1781

Factor impacto JCR: 4.2 (2023)

Categ. JCR: PSYCHIATRY rank: 50 / 276 = 0.181 (2023) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 50 / 276 = 0.181 (2023) - Q1 - T1

Factor impacto CITESCORE: 17.4 - Biological Psychiatry (Q1) - Psychiatry and Mental Health (Q1)

Factor impacto SCIMAGO: 2.189 - Psychiatry and Mental Health (Q1) - Biological Psychiatry (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CD20-00177
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI11-00325
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI14-00612

Tipo y forma: Article (Published version)

Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)